Trimodal Therapy Plus Atezolizumab in Muscle-invasive Bladder Cancer
Status:
Unknown status
Trial end date:
2020-12-30
Target enrollment:
Participant gender:
Summary
This is a single arm phase II trial to (1) evaluate safety and toxicity profile of
intravenous Atezolizumab (anti-PDL-1) administered in combination with TMT in patients with
MIBC, (2) To determine the loco-regional control rate (LCR) of TMT combined with PDL-1
blockade.
Phase:
Phase 2
Details
Lead Sponsor:
McGill University Health Center McGill University Health Centre/Research Institute of the McGill University Health Centre